Original BioMedicals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Revenue	0.38	-	0.04	0.11	-	Upgrade
Revenue Growth (YoY)	-	-	-59.81%	-	-	Upgrade
Cost of Revenue	0.08	-	0.01	0.01	-	Upgrade
Gross Profit	0.31	-	0.04	0.1	-	Upgrade
Selling, General & Admin	57.65	45.28	34.59	17.36	11.92	Upgrade
Research & Development	47.26	33.05	24.71	22.91	20.74	Upgrade
Operating Expenses	104.9	78.33	59.3	40.27	32.67	Upgrade
Operating Income	-104.6	-78.33	-59.26	-40.18	-32.67	Upgrade
Interest Expense	-0.59	-0.87	-1.07	-1.2	-1.39	Upgrade
Interest & Investment Income	3.06	4.19	0.7	0.47	0.14	Upgrade
Currency Exchange Gain (Loss)	0.62	0.01	-0	0	-0	Upgrade
Other Non Operating Income (Expenses)	-	-	-0.03	0.62	0.04	Upgrade
EBT Excluding Unusual Items	-101.51	-75	-59.66	-40.28	-33.88	Upgrade
Pretax Income	-101.51	-75	-59.66	-40.28	-33.88	Upgrade
Net Income	-101.51	-75	-59.66	-40.28	-33.88	Upgrade
Net Income to Common	-101.51	-75	-59.66	-40.28	-33.88	Upgrade
Shares Outstanding (Basic)	66	66	49	47	42	Upgrade
Shares Outstanding (Diluted)	66	66	49	47	42	Upgrade
Shares Change (YoY)	0.72%	33.68%	4.87%	13.05%	50.66%	Upgrade
EPS (Basic)	-1.53	-1.14	-1.21	-0.86	-0.81	Upgrade
EPS (Diluted)	-1.53	-1.14	-1.21	-0.86	-0.81	Upgrade
Free Cash Flow	-96.96	-85.95	-27.81	-30.89	-26.86	Upgrade
Free Cash Flow Per Share	-1.46	-1.30	-0.56	-0.66	-0.65	Upgrade
Gross Margin	80.31%	-	81.39%	88.78%	-	Upgrade
Operating Margin	-27453.02%	-	-137818.61%	-37547.66%	-	Upgrade
Profit Margin	-26643.05%	-	-138746.51%	-37642.06%	-	Upgrade
Free Cash Flow Margin	-25448.29%	-	-64674.42%	-28864.49%	-	Upgrade
EBITDA	-99.88	-74.05	-54.64	-35.64	-27.43	Upgrade
D&A For EBITDA	4.72	4.29	4.62	4.54	5.24	Upgrade
EBIT	-104.6	-78.33	-59.26	-40.18	-32.67	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.